213 related articles for article (PubMed ID: 17105906)
1. Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis.
Ujike H; Sakai A; Nakata K; Tanaka Y; Kodaka T; Okahisa Y; Harano M; Inada T; Yamada M; Komiyama T; Hori T; Sekine Y; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Ann N Y Acad Sci; 2006 Aug; 1074():90-6. PubMed ID: 17105906
[TBL] [Abstract][Full Text] [Related]
2. No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence.
Morio A; Ujike H; Nomura A; Tanaka Y; Morita Y; Otani K; Kishimoto M; Harano M; Inada T; Komiyama T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Ann N Y Acad Sci; 2006 Aug; 1074():411-7. PubMed ID: 17105939
[TBL] [Abstract][Full Text] [Related]
3. Association study of the tumor necrosis factor-alpha gene and its 1A receptor gene with methamphetamine dependence.
Nomura A; Ujike H; Tanaka Y; Kishimoto M; Otani K; Morita Y; Morio A; Harano M; Inada T; Yamada M; Komiyama T; Hori T; Sekine Y; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Ann N Y Acad Sci; 2006 Aug; 1074():116-24. PubMed ID: 17105909
[TBL] [Abstract][Full Text] [Related]
4. [The human dihydropyrimidinase-related protein 2 (DRP-2) gene on chromosome 8p21 is associated with paranoid-type schizophrenia].
Nakata K; Ujike H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):33-7. PubMed ID: 15027329
[TBL] [Abstract][Full Text] [Related]
5. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis.
Ujike H; Harano M; Inada T; Yamada M; Komiyama T; Sekine Y; Sora I; Iyo M; Katsu T; Nomura A; Nakata K; Ozaki N
Pharmacogenomics J; 2003; 3(4):242-7. PubMed ID: 12931138
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis.
Ujike H; Katsu T; Okahisa Y; Takaki M; Kodama M; Inada T; Uchimura N; Yamada M; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):625-9. PubMed ID: 19275926
[TBL] [Abstract][Full Text] [Related]
7. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder.
Nishiyama T; Ikeda M; Iwata N; Suzuki T; Kitajima T; Yamanouchi Y; Sekine Y; Iyo M; Harano M; Komiyama T; Yamada M; Sora I; Ujike H; Inada T; Furukawa T; Ozaki N
Pharmacogenomics J; 2005; 5(2):89-95. PubMed ID: 15772696
[TBL] [Abstract][Full Text] [Related]
8. Association between neuropeptide Y gene and its receptor Y1 gene and methamphetamine dependence.
Okahisa Y; Ujike H; Kotaka T; Morita Y; Kodama M; Inada T; Yamada M; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Psychiatry Clin Neurosci; 2009 Jun; 63(3):417-22. PubMed ID: 19566775
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis.
Ujike H; Sato M
Ann N Y Acad Sci; 2004 Oct; 1025():279-87. PubMed ID: 15542728
[TBL] [Abstract][Full Text] [Related]
10. Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence.
Kobayashi H; Ide S; Hasegawa J; Ujike H; Sekine Y; Ozaki N; Inada T; Harano M; Komiyama T; Yamada M; Iyo M; Shen HW; Ikeda K; Sora I
Ann N Y Acad Sci; 2004 Oct; 1025():325-34. PubMed ID: 15542733
[TBL] [Abstract][Full Text] [Related]
11. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis.
Kishimoto M; Ujike H; Motohashi Y; Tanaka Y; Okahisa Y; Kotaka T; Harano M; Inada T; Yamada M; Komiyama T; Hori T; Sekine Y; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Biol Psychiatry; 2008 Jan; 63(2):191-6. PubMed ID: 17555717
[TBL] [Abstract][Full Text] [Related]
12. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia.
Morita Y; Ujike H; Tanaka Y; Uchida N; Nomura A; Ohtani K; Kishimoto M; Morio A; Imamura T; Sakai A; Inada T; Harano M; Komiyama T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Neurosci Lett; 2005 Mar; 376(3):182-7. PubMed ID: 15721218
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence.
Akiyama K
Ann N Y Acad Sci; 2006 Aug; 1074():125-34. PubMed ID: 17105910
[TBL] [Abstract][Full Text] [Related]
14. G72 gene is associated with susceptibility to methamphetamine psychosis.
Kotaka T; Ujike H; Okahisa Y; Takaki M; Nakata K; Kodama M; Inada T; Yamada M; Uchimura N; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1046-9. PubMed ID: 19482054
[TBL] [Abstract][Full Text] [Related]
15. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence.
Nomura A; Ujike H; Tanaka Y; Otani K; Morita Y; Kishimoto M; Morio A; Harano M; Inada T; Yamada M; Komiyama T; Sekine Y; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
Neurosci Lett; 2006 May; 400(1-2):158-62. PubMed ID: 16529859
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population.
Chanasong R; Thanoi S; Watiktinkorn P; Reynolds GP; Nudmamud-Thanoi S
Neurosci Lett; 2013 Sep; 551():58-61. PubMed ID: 23880023
[TBL] [Abstract][Full Text] [Related]
17. An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder.
Suzuki A; Nakamura K; Sekine Y; Minabe Y; Takei N; Suzuki K; Iwata Y; Kawai M; Takebayashi K; Matsuzaki H; Iyo M; Ozaki N; Inada T; Iwata N; Harano M; Komiyama T; Yamada M; Sora I; Ujike H; Mori N
Psychiatr Genet; 2006 Aug; 16(4):133-8. PubMed ID: 16829779
[TBL] [Abstract][Full Text] [Related]
18. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms.
Ide S; Kobayashi H; Ujike H; Ozaki N; Sekine Y; Inada T; Harano M; Komiyama T; Yamada M; Iyo M; Iwata N; Tanaka K; Shen H; Iwahashi K; Itokawa M; Minami M; Satoh M; Ikeda K; Sora I
Pharmacogenomics J; 2006; 6(3):179-88. PubMed ID: 16402083
[TBL] [Abstract][Full Text] [Related]
19. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.
Otani K; Ujike H; Sakai A; Okahisa Y; Kotaka T; Inada T; Harano M; Komiyama T; Hori T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Neurosci Lett; 2008 Mar; 434(1):88-92. PubMed ID: 18280655
[TBL] [Abstract][Full Text] [Related]
20. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers.
Ide S; Kobayashi H; Tanaka K; Ujike H; Sekine Y; Ozaki N; Inada T; Harano M; Komiyama T; Yamada M; Iyo M; Ikeda K; Sora I
Ann N Y Acad Sci; 2004 Oct; 1025():316-24. PubMed ID: 15542732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
